Plexera — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Private Company

Funding information not available

Overview

Plexera is a privately held company that has developed a proprietary technology platform centered on high-throughput microarray printing and label-free Surface Plasmon Resonance Imaging (SPRi). Its flagship product, the PlexArray HT Ultra workstation, enables real-time, multiplexed analysis of biomolecular interactions for applications in drug screening and target identification. The company operates as a platform and tools provider, serving the research and early development segments of the life sciences industry.

DiagnosticsProteomics

Technology Platform

Integrated platform for label-free biomolecular interaction analysis, comprising: High-throughput microarray printing; Gold and Silver Surface Plasmon Resonance Imaging (SPRi) instrumentation (PlexArray HT Ultra); Proprietary 3D surface chemistry for biochip functionalization; Optical crosslinking technology.

Opportunities

Growing demand for high-throughput, label-free analysis in drug discovery and proteomics drives the need for advanced SPRi systems.

Expansion into adjacent applications like gene therapy characterization and neurodegenerative disease research presents new market segments.

The integrated offering of instruments, specialized chips, and peptide libraries (JPT) creates a sticky, recurring revenue model.

Risk Factors

Faces intense competition from larger, established players in the label-free detection market.

Technological obsolescence risk if newer, alternative label-free methods gain broader adoption.

As a private company, may have limited resources for large-scale R&D and global commercial expansion compared to public competitors.

Competitive Landscape

Plexera competes in the label-free detection and microarray markets against major players like Cytiva (Biacore SPR systems), Bruker, and Reichert Technologies. Its differentiation is the combination of SPR with high-density microarray imaging (SPRi) for multiplexed analysis. It also faces competition from other label-free technologies such as BLI (Bio-Layer Interferometry) from Sartorius and various interferometric-based platforms.

More companies in Diagnostics & Precision Medicine →More companies in United States →